Griffiths Kayleigh, Pazderska Agnieszka, Ahmed Mohammed, McGowan Anne, Maxwell Alexander P, McEneny Jane, Gibney James, McKay Gareth J
Centre for Public Health, Queen's University Belfast, Belfast, UK.
Department of Endocrinology, Tallaght Hospital, Dublin 24, Ireland.
J Diabetes Res. 2017;2017:1314864. doi: 10.1155/2017/1314864. Epub 2017 May 9.
Persons with type 2 diabetes mellitus (T2DM) have an elevated risk of atherosclerosis. High-density lipoproteins (HDL) normally protect against cardiovascular disease (CVD), but this may be attenuated by serum amyloid A (SAA). In a case-control study of young females, blood samples were compared between subjects with T2DM ( = 42) and individuals without T2DM ( = 42). SAA and apolipoprotein AI (apoAI) concentrations, paraoxonase-1 (PON-1), cholesteryl ester transfer protein (CETP), and lecithin-cholesterol acyltransferase (LCAT) activities were measured in the serum and/or HDL and HDL subfractions. SAA concentrations were higher in T2DM compared to controls: serum (30 mg/L (17, 68) versus 15 mg/L (7, 36); = 0.002), HDL (1.0 mg/L (0.6, 2.2) versus 0.4 mg/L (0.2, 0.7); < 0.001), and HDL, (13 mg/L (8, 29) versus 6 mg/L (3, 13); < 0.001). Serum-PON-1 activity was lower in T2DM compared to that in controls (38,245 U/L (7025) versus 41,109 U/L (5690); = 0.043). CETP activity was higher in T2DM versus controls in HDL (232.6 mol/L (14.1) versus 217.1 mol/L (25.1); = 0.001) and HDL (279.5 mol/L (17.7) versus 245.2 mol/L (41.2); < 0.001). These results suggest that individuals with T2DM have increased SAA-related inflammation and dysfunctional HDL features. SAA may prove to be a useful biomarker in T2DM given its association with elevated CVD risk.
2型糖尿病（T2DM）患者患动脉粥样硬化的风险升高。高密度脂蛋白（HDL）通常可预防心血管疾病（CVD），但血清淀粉样蛋白A（SAA）可能会削弱这种保护作用。在一项针对年轻女性的病例对照研究中，对42例T2DM患者和42例非T2DM个体的血样进行了比较。测定了血清和/或HDL及HDL亚组分中的SAA和载脂蛋白AI（apoAI）浓度、对氧磷酶-1（PON-1）、胆固醇酯转运蛋白（CETP）和卵磷脂胆固醇酰基转移酶（LCAT）活性。与对照组相比，T2DM患者的SAA浓度更高：血清（30mg/L（17，68）对15mg/L（7，36）；P = 0.002）、HDL（1.0mg/L（0.6，2.2）对0.4mg/L（0.2，0.7）；P < 0.001）和HDL2（13mg/L（8，29）对6mg/L（3，13）；P < 0.001）。与对照组相比，T2DM患者的血清PON-1活性较低（38245U/L（7025）对41109U/L（5690）；P = 0.043）。在HDL中，T2DM患者的CETP活性高于对照组（232.6μmol/L（14.1）对217.1μmol/L（25.1）；P = 0.001）和HDL3（279.5μmol/L（17.7）对245.2μmol/L（41.2）；P < 0.001）。这些结果表明，T2DM患者存在与SAA相关的炎症增加和HDL功能障碍特征。鉴于SAA与CVD风险升高相关，它可能被证明是T2DM中一种有用的生物标志物。
